Xlife Sciences AG (XLSZ.XC)
Cboe UK · CHF · Healthcare · Biotechnology
CHF 8.68 (+0.00%) as of
Key statistics
- Market cap
- 51.01M
- EPS (TTM)
- -32.31
- Dividend yield
- 0.00%
- 52-week range
- 8.32 – 26.00
- Beta
- 0.50
- Revenue (TTM)
- 397.23k
- Profit margin
- 0.00%
- Volume
- 34.00
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indication areas; focuses in the areas of medical technology to develop innovative methods for diagnosing illnesses and/or patient monitoring; and deploys artificial intelligence to improve diagnostic methods and/or processes in the field of biotechnology. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zurich, Switzerland
- Employees
- 20
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- BROOKFIELD CORPORATION BROOKFIE (0KEH.L)
- Eurofins Scientific SE (ERFP.XC)
- STITCH FIX INC STITCH FIX ORD S (0L9X.L)
- IVF Hartmann Holding AG (VBSNZ.XC)
- AD PEPPER MEDIA INTERNATIONAL N (0OOS.L)
- EXMAR NV EXMAR NV ORD SHS (0EEV.L)
- HF COMPANY SA HF COMPANY ORD SH (0EOI.L)
- LEGGETT & PLATT INC LEGGETT & P (0JTT.L)